P

Polyclinic Bonifarm | Zagreb, Croatia

Research site

(Unclaimed)

Location

Aleksandra Hondla 2/11, Zagreb, Zagreb County, Croatia

Site insights

Top conditions

Top treatments

Dazodalibep

Etrasimod

695501

Apixaban

GLPG3667

Mirikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Enrolling

Sjögren's Syndrome

Drug: Dazodalibep

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered...

Active, not recruiting

Dermatomyositis

Drug: Placebo

Drug: GLPG3667

Locations recently updated

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Active, not recruiting

Sjogren's Syndrome

Drug: Dazodalibep

Drug: Placebo